Overview

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Novartis
Treatments:
Everolimus
Sirolimus